Akèy › Kansè Endomèt › Texas › Houston
Etid klinik pou Kansè Endomèt nan Houston, TX
68 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Lyndon Baines Johnson General Hospital, Houston
- UT MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Ap rekriteEtid obsèvasyon
- Total Women's Care of the Heights, Houston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Houston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Ap rekriteFaz 2
- M.D. Anderson Cancer Center, Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Ap rekriteFaz 3
- Houston Methodist Hospital ( Site 6057), Houston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
Ap rekriteEtid obsèvasyon
- MD Anderson Cancer Center, Houston
Sentinel Node Biopsy in Endometrial Cancer
Ap rekriteFaz 3
- Houston Methodist Hospital, Houston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Oncology Consultants, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas - MD Anderson Cancer Center, Houston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, Houston
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- M. D. Anderson Cancer Center, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson, Houston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Houston
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Ap rekriteFaz 2
- University of Texas, MD Anderson Cancer Center, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ap rekriteFaz 1
- Normunity Investigational Site, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
Ap rekriteEtid obsèvasyon
- The Harris Health System (LBJ), Houston
- MD Anderson Cancer Center, Houston
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Ap rekriteEtid obsèvasyon
- Houston Methodist Cancer Center (Data Collection Only), Houston
A Study of DM002 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT - Oncology - Houston, Houston
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Houston
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #129, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- MD Anderson Cancer Center, Houston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson, Houston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center, Houston
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Ap rekriteFaz 1/2
- M.D. Anderson Cancer Center, Houston
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Ap rekriteFaz 2
- MD Anderson Cancer Center - U of Texas, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Houston
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
Ap rekrite
- Baylor College of Medicine- McNair Campus, Houston
- Baylor College of Medicine, Houston
- Ben Taub General Hospital, Houston
- ak 1 plis
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Ap rekriteFaz 1
- The University of Texas M.D. Anderson Cancer Center, Houston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- Oncology Consultants, P.A., Houston
- The University of Texas M. D. Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
Ap rekriteVolontè an sante akeyi
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
HPV Vaccine, Imiquimod, and Metformin Combination Trial
Ap rekriteFaz 2
- Baylor St. Luke's Medical Center- Dan L. Duncan Comprehensive Cancer Center, Houston
- Harris Health Smith Clinic, Houston
Etid Kansè Endomèt nan lòt vil
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Queens, NY25 etid
- Columbus, OH25 etid
- Chicago, IL25 etid
- Oklahoma City, OK25 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè pankreyas61 etid
- Melanom59 etid
- Karsinòm selil skuamèz tèt ak kou47 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.